Dr. Ahmed El-Sobky, Chairman of the Healthcare Authority and General Supervisor of the Universal Health Insurance Project, and Ms. Gehan El Mor, Chairman and Managing Director of Novartis Egypt, witnessed the signing of a Memorandum of Understanding (MoU) between the Healthcare Authority and Novartis Egypt to support cancer patients.
The MoU was signed by Dr. Amir El-Telwany, Executive Director of the Healthcare Authority, on behalf of the Authority, and Dr. Mohamed Sabry, Head of Market Access and Patient Solutions Unit at Novartis Egypt, on behalf of the company.
Dr. El-Sobky emphasized that this agreement aligns with the Authority’s ongoing efforts to establish strategic collaborations with leading global healthcare companies, aiming to enhance the quality of cancer care, with a particular focus on breast cancer. He highlighted that this partnership will improve healthcare providers’ capabilities, advance early diagnosis, and optimize treatment pathways in accordance with international healthcare standards, reinforcing Egypt’s national efforts to combat non-communicable diseases (NCDs) and enhance overall healthcare services.
He further emphasized that raising health awareness and promoting medical literacy among citizens is a top priority for the Healthcare Authority. Through this collaboration, Novartis will contribute to community-wide awareness campaigns and comprehensive educational initiatives that will enhance public knowledge about early detection and improve patient experiences in breast cancer care.
According to the MoU, the collaboration between the Healthcare Authority and Novartis Egypt will focus on:
Medical Education & Training:
Digital Healthcare Solutions:
Awareness & Screening Campaigns:
Dr. El-Sobky stressed the importance of documenting the success story of this strategic partnership between the Healthcare Authority, representing the public sector, and Novartis Egypt, as a leading global pharmaceutical company. He also highlighted the significance of sharing the impact of this collaboration on international platforms, similar to the previous partnership between Novartis and the Healthcare Authority in the field of cardiology.
Ms. Gehan El Mor, Chairman of Novartis Egypt, expressed pride in the partnership’s impact on patient care, affirming Novartis’ ongoing commitment to improving treatment outcomes.
She stated:
"The collaboration between Novartis and the Healthcare Authority underscores our unwavering commitment to breast cancer control and our alignment with Egypt’s Vision 2030 for healthcare development. Novartis remains dedicated to enhancing treatment outcomes and advancing breast cancer care in Egypt through early detection strategies and optimal disease management."
She further emphasized that Novartis has been at the forefront of pioneering cancer research for decades, with a focus on bridging treatment gaps and delivering innovative solutions.
"Through strategic partnerships and evidence-based approaches, Novartis aims to empower both healthcare providers and patients, ensuring a brighter future in the fight against breast cancer."
The MoU between the Healthcare Authority and Novartis Egypt represents a major step forward in cancer care enhancement through education, digital transformation, and awareness programs. This landmark partnership will not only improve treatment outcomes but also foster a culture of early detection, helping Egypt achieve its long-term healthcare goals.
